Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.71 |
| ▸ | VEGFA | P15692 | 10/20 | 0.71 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12669231 | 0.84 | EGLN1 (0.72) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL272670 | 0.83 | EGLN1 (0.88) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL273704 | 0.83 | EGLN1 (1.00) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL272319 | 0.81 | VEGFA (0.75) | EGLN1VEGFATP53HTTMEN1 | |
| SCHEMBL12599456 | 0.80 | EGLN1 (0.80) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL271709 | 0.78 | EGLN1 (0.64) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL1774277 | 0.78 | EGLN1 (1.00) | EGLN1VEGFAKDM4EHTTMEN1 | |
| SCHEMBL14900099 | 0.78 | EGLN1 (0.69) | EGLN1VEGFABRD4KDM4ETP53 | |
| SCHEMBL12649393 | 0.77 | EGLN1 (0.88) | EGLN1VEGFACYP2D6SMN1; SMN2POLB | |
| SCHEMBL271531 | 0.77 | EGLN1 (0.63) | EGLN1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | claimed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | claimed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | claimed |
| EP-2496082-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | claimed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| EP-1558579-B1 | N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS | PROCTER & GAMBLE (US) | 2007-09-12 | — | — | EP | claimed |
| US-6930117-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-16 | — | — | US | claimed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | claimed |
| CN-116018136-A | Hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of aging-related disorders | 百爱及生物医药公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-4142721-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | Bioage Labs, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | BioAge Labs, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-7247648-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050234045-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-20 | — | — | US | disclosed |
| US-6930117-B2 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885BRD4 2466/4885 |
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | HIF1AN, HIF1A, P4HA1 | EGLN1 11/4885VEGFA 384/4885BRD4 3761/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | EGLN1 926/4885VEGFA 3112/4885BRD4 1351/4885 |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, IFNG, CD4 | EGLN1 1060/4885VEGFA 2758/4885BRD4 1148/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885BRD4 2594/4885 |
| US-20050234045-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, IFNG, CD4 | EGLN1 1182/4885VEGFA 3064/4885BRD4 1247/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885BRD4 2466/4885 |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885BRD4 2466/4885 |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885BRD4 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.